Human Cancer Biology

SHP2 Is Overexpressed and Inhibits pSTAT1-Mediated APM Component Expression, T-cell Attracting Chemokine Secretion, and CTL Recognition in Head and Neck Cancer Cells

Michael S. Leibowitz¹, Raghvendra M. Srivastava², Pedro A. Andrade Filho², Ann Marie Egloff², Lin Wang³, Raja R. Seethala³, Soldano Ferrone¹,4, and Robert L. Ferris¹,2,5

Abstract

Purpose: Human leukocyte antigen (HLA) class I antigen processing machinery (APM) component downregulation permits escape of malignant cells from recognition by cytotoxic T lymphocytes (CTL) and correlates with poor prognosis in patients with head and neck cancer (HNC). Activated STAT1 (pSTAT1) is necessary for APM component expression in HNC cells. We investigated whether an overexpressed phosphatase was responsible for basal suppression of pSTAT1 and subsequent APM component-mediated immune escape in HNC cells.

Experimental Design: Immunohistochemical staining and reverse transcription PCR of paired HNC tumors was performed for the phosphatases src homology domain-containing phosphatase (SHP)–1 and SHP2. Depletion of phosphatase activity in HNC and STAT1⁰ tumorn cells was achieved by siRNA knockdown. HLA class I–restricted, tumor antigen-specific CTL were used in IFN-γ ELISPOT assays against HNC cells. Chemokine secretion was measured after SHP2 depletion in HNC cells.

Results: SHP2, but not SHP1, was significantly upregulated in HNC tissues. In HNC cells, SHP2 depletion significantly upregulated expression of pSTAT1 and HLA class I APM components. Overexpression of SHP2 in nonmalignant keratinocytes inhibited IFN-γ-mediated STAT1 phosphorylation, and SHP2 depletion in STAT1⁰ tumor cells did not significantly induce IFN-γ–mediated APM component expression, verifying STAT1 dependence of SHP2 activity. SHP2 depletion induced recognition of HNC cells by HLA class I–restricted CTL and secretion of inflammatory, T-cell attracting chemokines, RANTES and IP10.

Conclusion: These findings suggest for the first time an important role for SHP2 in APM-mediated escape of HNC cells from CTL recognition. Targeting SHP2 could enhance T-cell–based cancer immunotherapy.

Clin Cancer Res; 19(4); 1–11. ©2012 AACR.

Introduction

In the majority of cases, T-cell–based cancer immunotherapies have yielded detectable immune responses in the absence of appreciable clinical activity (1). Several immune escape mechanisms have been identified in patients with head and neck squamous cell carcinoma (HNC). At the effector phase level, they include recruitment of regulatory T cells and myeloid-derived suppressor cells into the tumor microenvironment (2) and reduction of absolute T lymphocyte counts (3). At the target cell level, a major mechanism is represented by downregulation of the antigen processing machinery components; this abnormality leads to poor tumor antigen processing and presentation (4–7). As a result, HNC cells are poorly recognized by cognate HLA class I antigen-restricted, tumor antigen–specific cytotoxic T lymphocytes (CTL; refs. 4, 7, 8). Interestingly, antigen processing machinery (APM) component downregulation correlates with poor prognosis in patients with HNC (6), showing that this escape mechanism is clinically significant. The molecular mechanism for this poor tumor antigen presentation has been characterized only to a limited extent.

Previous work has shown that treatment of HNC cells with IFN-γ upregulates APM components and restores tumor antigen–specific CTL lysis in vitro (4). In prior studies, we have shown that APM expression and T-cell recognition require IFN-γ-STAT1 pathway activation (4, 9). The low basal pSTAT1 levels in HNC cells led us to investigate...
regulatory mechanisms that disrupt STAT1 activation, APM component expression, T-cell recruitment, and subsequent recognition of HNC cells. Since we have recently found that HNC cells express basal total (unphosphorylated) STAT1, but not activated pSTAT1 (9), we hypothesized that a negative regulator of STAT1 phosphorylation might be responsible for low APM component expression and CTL escape in HNC cells. Src homology-2 domain-containing phosphatase (SHP)-2 has been suggested as a negative regulator of the JAK-STAT signal transduction pathway (10, 11) but it has not been implicated in tumor immune escape. Furthermore, SHP2 overexpression and/or hyperactivity have been shown in leukemia, breast, and bladder cancers (12, 13). Thus, we investigated whether overexpression of SHP2 might provide a novel mechanism for CTL escape through dephosphorylation of pSTAT1 in cancer cells, reducing expression of HLA class I APM components as well as proinflammatory cytokines and chemokines.

Materials and Methods

Cell lines

The HLA-A*0201+ HNC cell lines, PCI-13 and SCC-90 (14) and HLA-A*0201- cell lines, SCC-4 and PCI-15B were characterized and described previously (15). All tumor cell lines were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich Inc) supplemented with 10% FBS (Mediatech), 2% l-glutamine, and 1% penicillin/streptomycin (Life Technologies). Keratinocytes were described previously (16) and grown in keratinocyte serum-free medium (Keratinocyte-SFM; Life Technologies) supplemented with bovine pituitary extract. Parental 2fTGH (STAT1+/+) and U3A (STAT1-/-) fibrosarcoma cells (a kind gift from Dr. George Stark, Cleveland Clinic Foundation, Cleveland, OH) were cultured in Iscove’s Modified Dulbecco’s Medium (Life Technologies) supplemented with 10% FBS (Mediatech), 2% l-glutamine, and 1% penicillin/streptomycin (Life Technologies).

Cytokines

Human IFN-γ was purchased from InterMune. IFN-γ concentration in cell culture supernatants was determined by human IFN-γ ELISA kit (R&D systems) according to the manufacturer’s instructions. In the experimental conditions used, 100 U/mL of recombinant IFN-γ equated to 1,464 pg/mL using this ELISA kit.

Antibodies

Anti-HLA-A,B,C mAb (W6/32; EBiSciences) and anti-HLA-DR (L243) mAb (BioLegend) were used in ELISPOT assays. LMP2-specific mAb SY-1 (17), TAP1-specific mAb NOB-1, TAP2-specific mAb NOB-2, and calreticulin-specific mAb TO-11, were developed and characterized as described (17, 18). Fluorescein isothiocyanate (FITC)-conjugated IgG anti-mouse mAb (Life Technologies) was used as a secondary antibody for APM components. The intracellular pSTAT staining was conducted using phycoerythrin (PE)-conjugated irrelevant IgG2a mAb isotype control, PE-conjugated phosphorylated tyrosine 701 STAT1 mAb (pSTAT1 Tyr701). Alexa Fluor 647-conjugated total STAT1 mAb, FITC-conjugated phosphorylated serine 727 STAT1 mAb (pSTAT1 Ser 727), PE-conjugated STAT1 Tyr 701, pSTAT3 Tyr705 mAb, and FITC-conjugated phosphorylated serine 727 STAT3 mAb (pSTAT3 Ser 727) were purchased from BD Biosciences. Anti-pSTAT1 Tyr701 mAb (Cell Signaling Tech), anti-total STAT1 (C-24) polyclonal (pAb; Santa Cruz Biotech), anti-β-actin mAb (Sigma-Aldrich Inc.), anti-rabbit IgG-HRP (Promega), anti-mouse IgG-HRP (Bio-Rad), anti-phosphorylated JAK-1 (Tyr1022/1023) mAb, anti-phosphorylated JAK-2 (Tyr1007/1008) mAb (Cell signaling Tech), anti-total JAK-1 mAb, and anti-total JAK-2 mAb (Santa Cruz Biotech) were used in immunoblot analyses.

Immunohistochemistry

Protein levels were evaluated by immunohistochemical (IHC) staining of tumor and adjacent mucosal specimens arrayed in a previously described tissue microarray (TMA; ref. 19). For the studies presented here, the maximum number of evaluable tumor specimens was 46; 16 of these tumors had arrayed adjacent mucosal tissues available for analysis. TMA quality assessment and morphologic confirmation of tumor or normal histology was conducted using one hematoxylin and eosin (H&E)-stained slide for every 10 tissue sections. Arrayed tissues were immunohistochemically stained for SHP1 and SHP2 and tissue levels were evaluated semiquantitatively. Before incubation with anti-SHP1 (Santa Cruz Biotech) or anti-SHP2 (Santa Cruz Biotech) antibodies for 60 minutes at room temperature, antigen retrieval was conducted using citrate pH 6 buffer (Dako) followed by incubation with a 3% hydrogen peroxide solution for 5 minutes at room temperature. The tissue specimens were then blocked with calf serum block (Life Technologies) for 10 minutes at room temperature. SHP1 staining was developed using Dako Dual Envision+ for 30 minutes at room temperature followed by incubation with Substrate Chromagen for 5 minutes at room temperature. Slides were
counterstained with Harris Hematoxylin, and cytoplasmic and nuclear staining intensity (0–3) and percentage of tumor cells to the nearest 5% were determined separately by a head and neck cancer pathologist. An IHC score was derived from the product of the intensity and percentage of tumor stained, and IHC scores for each core of a specimen were averaged.

Quantitative real-time reverse transcription PCR

Total RNA from tumor samples and normal mucosa was extracted using Trizol reagent (Invitrogen) and purified using RNA cleanup (Qiagen), followed by DNase digestion (Ambion) according to manufacturer’s instructions. The concentration and purity of RNA was determined by measuring absorbance at 260 and 280 nm. RNA was used for first strand cDNA synthesis using random hexamers and MuLV reverse transcriptase (Applied Biosystems) according to the manufacturer’s instructions. PCR probes for SHP2 (Hs00743983_s1) and β-actin (Hs99999903_m1) were purchased from Applied Biosystems for TaqMan Gene Expression Assay. Real-time PCR cycling was conducted (7700 Real-Time PCR System; Applied Biosystems) under the following conditions: denaturation at 95°C for 10 seconds, annealing at 60°C for 15 seconds, and extension at 72°C for 30 seconds. An initial denaturation step at 95°C for 5 minutes and a final extension step at 72°C for 10 minutes were also included. PCR was conducted for 40 cycles. β-Actin was amplified as an internal control. All of the experiments were carried out in duplicates. Relative expression of the SHP2 gene to endogenous control gene (β-actin) was calculated using the ΔC(T) method: relative expression = 2°ΔC(T), where ΔC(T) = C(T (shp2)) - C(T (β-actin)).

Immunoblot analysis

Cells were lysed in 10 mmol/L Tris HCl, 5 mmol/L EDTA, 50 mmol/L NaCl, 30 mmol/L Na2HPO4, 50 mmol/L NaF, 1 mmol/L NaVO4, 1% Triton X-100, 1 mmol/L phenylmethylsulfonylfluoride (PMSF) and vortexed for at least 1 minute at 4°C, sonicated for 6 seconds at 20% of the maximum potency (Cole Parmer Instrument) and centrifuged at 4°C, 16,100 x g for 15 minutes. The supernatant protein was normalized and 40 to 60 μg of protein were size fractionated through a 4 to 12% SDS-PAGE gel (Lonza), transferred to a polyvinylidene difluoride (PVDF) membrane (Millipore) and immunoblotted with the indicated antibodies.

Intracellular flow cytometry for APM component, pSTAT1, and total STAT1 expression

Briefly, the cells were fixed using 1.5% paraformaldehyde for 10 minutes at room temperature and permeabilized with 100% methanol for at least 24 hours at −20°C. Cells were then washed in 2% fetal calf serum (FCS)/PBS (FACS buffer), and stained with either a PE-conjugated primary STAT-specific mAb or sequentially by incubation with an unconjugated primary APM component-specific mAb and then with a FITC-conjugated anti-mouse secondary mAb. Both incubations were for 30 minutes at room temperature. FACS analysis was performed on the same day as staining. Isotype control antibody staining was set at a mean fluorescence intensity (MFI) of 5 on an EPICS XL cytometer (Beckman Coulter) or subtracted from each condition and cell line tested. A minimum of 10,000 cells were collected per test. Analyses were conducted using EXPO32 ADC software (Beckman Coulter), pSTAT1, pSTAT3, and APM component expression was determined on the basis of MFI and was expressed as a mean ± SEM of the results obtained in at least 3 independent experiments.

Transfection of cells with siRNA

HNC cell lines were transfected at 30% to 40% confluence with SHP1, SHP2, or a nontargeting siRNA control (Ambion), Lipofectamine RNAi max (Life Technologies), and OptiMem I (Life Technologies) according to the Lipofectamine RNAi max instructions.

SHP1: 5'-GGUGAACCACUAAUUGGAUCCITT-3’ (s) and 5’-GAUCCGAALAAUGGGUCACCTG-3’ (as)

SHP2: 5'-GGAGAACCGGUUUUGAUUCUJT-3’ (s) and 5’-AAUAAGCAGACACGUGCCCTC-3’ (as)

Non-targeting: 5’-AGIUACAGCAAGAUGCGUGGT-3’ (s) and 5’-CCGUAUUGCGUUGUGCUGU-3’ (as)

SHP2 plasmids

Keratinocytes were transfected at 80% to 90% confluence with wild-type SHP2 (pcDNA3.1-myct-His-SHP2) or mutant SHP2 (C4593) plasmid constructs (10 μg/ml; a kind gift from Dr. Gibbes Johnson, U.S. Food and Drug Administration, Silver Spring, MD). Lipofectamine 2000 reagent (Life Technologies) was used at a 1:2 dilution in OptiMem I (Life Technologies) according to the Lipofectamine 2000 instructions.

ELISPOT assay

ELISPOT assays were conducted as described (20). Briefly, multiscreen HTS-HA filter plates (Millipore) were coated with anti-human IFN-γ mAb 1-D1K (Mabtech; 10 μg/mL in PBS) overnight at 4°C. Plates were washed with PBS and then blocked for 1 hour at 37°C with DMEM supplemented with 10% human serum. EGFR 853–861 (20) and p53 65–73 (21, 22) specific CTL were added to wells in triplicate (5 x 10⁴) and then HNC cells (5 x 10⁴). Following an 18 to 24 hour incubation at 37°C, plates were washed with PBS/0.05% Tween 20 (PBS-T), and incubated with biotinylated anti-IFN-γ mAb (Mabtech; 2 μg/mL) for 4 hours at 37°C. Plates were washed with PBS-T avidin-peroxidase complex (Vector Laboratories) for 1 hour at room temperature and then peroxidase staining was conducted with 3,3’,5’-tetramethylbenzidine (Vector Laboratories) for 4 minutes. Spots were enumerated in triplicate wells as a mean ± SE using computer-assisted video image analysis software (Cellular Technology Ltd.). HLA class I–restricted recognition of the target cells by CTL was assessed by using the anti-HLA
class I–specific mAb W6/32 (10 μg/mL) and the specificity of the inhibition was assessed using the HLA-DR–specific mAb L243 (10 μg/mL).

Chemokine expression assay
HNC cells were assayed for expression of various cytokines and chemokines using a human cytokine 30-plex panel (Life Technologies) as previously described (23), 48 hours after siRNA knockdown of SHP2 or irrelevant target.

Statistical analysis
Data are expressed as a mean ± SE of the results obtained in at least 3 independent experiments. A 2-tailed t test was used to calculate whether observed differences were statistically significant, defined as P < 0.05. The signed rank test was used to evaluate differences in SHP1 and SHP2 levels between paired tumor and adjacent mucosal tissues and statistically significance was defined as P < 0.05.

Results
SHP2 but not SHP1 is overexpressed in HNC tissues
Previous work showed that pSTAT1 is required for APM component expression in HNC cells (9, 24), and that the STAT1 agonist, IFN-γ, induced APM component upregulation and CTL recognition (4). Interestingly, we found that basal levels of pSTAT1 are undetectable in HNC cells, despite abundant expression of total STAT1 protein (9). To identify a mechanism for this phenotype, we tested whether a protein tyrosine phosphatase might be responsible for the dephosphorylation of activated STAT1. First, a panel of HNC cells, PCI-13, SCC-90, SCC-4, and PCI-15B, were treated with a broad phosphatase inhibitor, sodium orthovanadate (SOV). After 24 hours of treatment with SOV (100 μmol/L), pSTAT1 levels were found to be significantly upregulated in these cells by immunoblot analysis (data not shown). These data indicated that protein tyrosine phosphatases may contribute to the basal dephosphorylation of STAT1 in HNC cells.

Both SHP1 (25, 26) and SHP2 (10) have been suggested to be negative regulators of STAT1 phosphorylation. To assess SHP1 and SHP2 expression in human HNC, IHC staining of a clinically annotated TMA cohort of HNC patients was performed on paired tumor and normal mucosa. Interestingly, IHC analysis revealed that SHP2 was significantly overexpressed in tumor cells compared with normal mucosa (Fig. 1A; P = 0.002, signed rank test). Moreover, quantitative reverse transcription PCR analysis also showed higher levels of SHP2 transcript in tumor samples compared with normal mucosa (Fig. 1B; P < 0.05). This difference is selective, as no significant difference in SHP1 expression was detected between tumor and normal mucosa (Supplementary Fig. S1). Therefore, we investigated the role of overexpressed SHP2 in HNC cells.

Figure 1. SHP2 is overexpressed in HNC tissue but not in normal mucosa. A, HNC tumors and normal adjacent mucosa were stained with an anti-SHP2 mAb (as described in Materials and Methods). The IHC semiquantitative score was derived by 2 independent pathologists, by multiplying the staining intensity (scored as 0–3) by the percent of tumor cells stained (0%–100%), to the nearest 5%. IHC scores for each core of a specimen were averaged (n = 14) and statistically analyzed. Representative examples at ×200 magnification of SHP2 from HNC tissue and normal mucosa are provided. B, cDNA from HNC tumors (n = 33) and normal adjacent mucosa (n = 11) were subjected to quantitative real-time PCR analysis (as described in Materials and Methods). Relative expression of shp2 transcript to endogenous control gene (β-actin) was calculated using the △C T method: relative expression = 2 -△△C T, where △△C T = △C (shp2) - △C (β-actin). Two-tailed unpaired t test was conducted for statistical analysis.
SHP2 depletion upregulates pSTAT1, pJAK-1/2, and total STAT1 in HNC cells

Using siRNA (100 nmol/L, 48 hours), we obtained about 70% knockdown of SHP2 protein in PCI-13 (Fig. 2A) and SCC-90 cells (Fig. 2G). SHP2 knockdown significantly reduced SHP2 expression in HNC cells by Western blot analyses. SHP2 depletion also significantly upregulated pSTAT1 and its target gene product STAT1 as determined by intracellular flow cytometry and immunoblotting compared with control siRNA in (B, C, E) PCI-13 and (H, I, K) SCC-90 cells. SHP2 depletion also upregulated pJAK1 (Tyr1022/1023) and pJAK2 (Tyr 1007/1008) compared with control siRNA in (F) PCI-13 and (L) SCC-90 cells. The cells were treated with IFN-γ (100 U/mL = 1,464 pg/mL, 48 hours) as a positive control for STAT1 phosphorylation. Data represent 3 independent experiments and error bars indicate SE.
potential mechanism, HNC cells were treated with conditioned media from the same cell lines that were previously treated with IFN-γ (100 U/mL, 48 hours), or transfected with control or SHP2 siRNA (100 nmol/L, 48 hours). Interestingly, HNC cells treated with SHP2 siRNA conditioned media induced STAT1 (Tyr) 701 phosphorylation (data not shown).

SHP2 depletion upregulates HLA class I APM component expression in HNC cells

Next, we investigated whether SHP2 depletion and subsequent enhancement of pSTAT1 led to an upregulation of HLA class I APM component expression in HNC cells. Indeed, SHP2 depletion by siRNA (100 nmol/L, 48 hours) induced significant upregulation of APM components in both PCI-13 and SCC-90 cells compared with control siRNA-treated cells (Fig. 3A–B; P < 0.003, 2-tailed t test). STAT1 phosphorylation induced by SHP2 depletion did not upregulate all of the APM components, as no change was detected in the expression of calreticulin, a non-IFN-γ-pSTAT1–inducible APM component (Fig. 3A and B). IFN-γ (100 U/mL, 48 hours), a well-characterized agonist of HLA class I APM component expression was used to compare relative APM component induction following siRNA transfections. In addition to upregulating APM components, SHP2 depletion by siRNA (100 nmol/L, 48 hours) also significantly upregulated HLA class I molecule expression compared with control siRNA-treated HNC cells (Fig. 3C and D; P < 0.02, 2-tailed t test).

SHP2 regulates TAP1/2 expression in a STAT1-dependent fashion

We then examined whether transfection of SHP2 conferred a similar phenotype of APM component down-regulation in nonmalignant keratinocytes, and whether this effect was dependent on STAT1. Interestingly, cultured keratinocytes have significantly higher basal activated STAT1 and IFN-γ–induced pSTAT1 compared with HNC cell lines, PCI-13 and SCC-90 (data not shown). Furthermore, overexpression of wild-type (WT) SHP2 in keratinocytes decreased both basal and IFN-γ–induced STAT1 phosphorylation compared with dominant negative, mutant SHP2 showing that SHP2 overexpression suppressed STAT1 activation in epithelial cells (Fig. 4A). In addition, IFN-γ–induced TAP1/2 expression in STAT1+/− fibrosarcoma cells were significantly increased after SHP2 depletion compared with both IFN-γ treatment alone and control siRNA, and this effect was abrogated in STAT1+/− fibrosarcoma cells (Fig. 4B and C). These data verify that SHP2 mediates APM component
upregulation through STAT1 activation, and supports the notion that SHP2 overexpression confers an "escape" phenotype of APM component downregulation in HNC cells.

**Figure 3.** SHP2 depletion upregulates HLA class I APM components. PCI-13 and SCC-90 cells were untreated, treated with IFN-γ (100 U/mL = 1,464 pg/mL, 48 hours), transfected with control siRNA (100 nmol/L, 48 hours) or SHP2 siRNA (100 nmol/L, 48 hours). Flow cytometric analyses of intracellular stained cells for TAP1, TAP2, and LMP2 APM components in (A) PCI-13 and (B) SCC-90 cells. Calreticulin, a non-IFN-γ–inducible APM component, was included to control for global changes in protein expression following transfection. MFI was measured and error bars indicate SE. Data represent 3 independent experiments and error bars indicate SE. PCI-13 (C) and SCC-90 (D) cells were treated as described above, and HLA class I expression was measured by flow cytometric MFI. Data represent 3 independent experiments and error bars indicate SE.

**Figure 4.** SHP2 decreases basal and IFN-γ induced pSTAT1 and TAP1/2 expression. A, keratinocytes transfected with wild-type SHP2 decreased basal and IFN-γ(10 U/mL = 146.4 pg/mL, 30 minutes) induced pSTAT1 compared with mutant SHP2. C, parental 2TGH (STAT1+/+) and U3A (STAT1−/−) fibrosarcoma cells were treated with IFN-γ (10 U/mL = 146.4 pg/mL) for 48 hours alone or 24 hours after transfection with SHP2 (50 nmol/L) or control siRNA. Flow cytometric analyses were used to determine TAP1 and TAP2 expression and the data were plotted by MFI. Data represent 3 independent experiments and error bars indicate SE.

**SHP2 depletion induces HNC cell recognition by tumor antigen-specific CTL**

The observation that SHP2 depletion significantly upregulated pSTAT1 and HLA class I APM components
promoted our investigation into whether SHP2 depletion-induced HNC cell recognition by CTL. Indeed, SHP2 depletion significantly increased PCI-13 and SCC-90 cell recognition by EGFR853–861 and p5365–73-specific CTL (Fig. 5A–B). As such, SHP2 depletion-induced HNC cell recognition by CTL. Indeed, SHP2 depletion significantly increased PCI-13 and SCC-90 cell recognition by EGFR853–861 and p5365–73-specific CTL (Fig. 5A–B). The recognition of HNC cells by tumor antigen-specific CTL is HLA class I-restricted, as it was inhibited by the HLA-A,-B,-C-specific mAb W6/32, but was not affected by HLA-DR-specific mAb L243.

SHP2 depletion induces secretion of chemokines by HNC cells

To investigate downstream effects of SHP2 depletion and pSTAT1 activation in HNC cells, we conducted multiplex ELISA assays (Luminex) to measure the secretion of several cytokines and chemokines. Interestingly, significantly elevated levels of RANTES and IP10 were detected in the supernatants of HNC cells after SHP2 depletion by siRNA (100 nmol/L, 48 hours) compared with cells transfected with control siRNA (Fig. 6A–B). Under similar conditions, cytokines induced by interferon-gamma (MIG) was not secreted by HNC cells after SHP-2 depletion, whereas it was secreted after these cells were incubated with IFN-γ for 48 hours (Fig. 6A and B). Notably, cytokines that induce STAT1 phosphorylation such as IFN-γ (Fig. 6A and B) and IFN-α (data not shown) were not detected in the supernatants of HNC cells after SHP2 depletion despite expression of IFN receptors on HNC cells (3). Other cytokines and chemokines that were analyzed in this multiplex ELISA panel include IL-1β, IL-1RA, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-13, IL-15, IL-17, TNF-α, GM-CSF, G-CSF, Eotaxin, MCP-1, MIP-1α, MIP-1β, EGF, HGF, VEGF) were not detected (data not shown). Thus, SHP2 overexpression confers an immunosuppressive phenotype by reducing pSTAT1-mediated APM component expression and CTL recognition of HNC cells, and inhibits some proinflammatory, Th1 cell recruiting chemokines from the tumor microenvironment.

Discussion

Multiple mechanisms are used by tumor cells to escape recognition and elimination by the immune system. We describe a novel mechanism responsible for the phenotype of HLA class I APM component downregulation, namely suppression of STAT1 activation, leading to tumor cell escape from tumor antigen-specific CTL recognition and lysis, a widely observed phenomenon in many human cancers (4, 7, 27). These defects seem to be dependent on overexpression of SHP2, an SH2 domain-containing tyrosine phosphatase, which was found to be highly overexpressed in vivo in HNC tumor tissues (Fig. 1), compared with surrounding normal epithelium. SHP2 is overexpressed and/or hyperactive in multiple malignancies (12, 13, 28–30); however, few studies have investigated their impact on immune cell migration and recognition of tumor cells (31–34). To the best of our knowledge, this is the first report to show that SHP2 is significantly overexpressed in HNC tissue (Fig. 1) with important biologic consequences.
Our *in vitro* results show that SHP2 negatively regulates STAT1 phosphorylation in HNC cells. Expression of WT SHP2 depletion upregulated basal levels of pSTAT1 and total STAT1 (Fig. 2B, C, E, H, I, and K) and significantly augmented TAP1/2 expression by IFN-γ in STAT1-expressing cells but not in STAT1-deficient cells (Fig. 4B and C). We did not observe differences in TAP1 expression after SHP2 depletion without pretreatment with IFN-γ and STAT-1−/− fibrosarcoma tumor cell lines, but details of the immune escape mechanisms in these unique fibrosarcoma cells is an interesting question of interest in our future studies. Fibrosarcoma tumor cells likely have other mechanisms that suppress APM expression beyond SHP2 activity and that the IFN-γ overcomes those other mechanisms.

As pSTAT1 homodimers are important regulators of APM component genes (9, 24), our observation that pSTAT1 was upregulated in response to SHP2 (but not SHP1) depletion in HNC cells suggested that this effect could be sufficient to induce APM component expression, at a level comparable with that induced by IFN-γ treatment. Indeed, HLA class I APM component expression was upregulated after SHP2 depletion (Fig. 3), and potentially induced HNC cell recognition by tumor antigen-specific CTL (Fig. 5). Interestingly, knockdown of SHP2 also induced HNC cell secretion of proinflammatory, TH1-associated chemokines, RANTES and IP-10 (Fig. 6). These findings have potential clinical significance because SHP2 is upregulated in HNC tumors *in vivo*, suggesting that targeting SHP2 could increase the immunogenicity of HNC cells through upregulation of HLA class I APM components while chemottracting naïve and memory (CCR5+) and T111 (CXCR3+) lymphocytes (35). This strategy could overcome a major limitation of T-cell–based cancer immunotherapy, which is the reliance on the tumor cell to serve as a target for recognition by tumor antigen-specific T lymphocytes.

APM component downregulation as an escape mechanism (6, 7) of HNC cells from CTL recognition also correlates with poor prognosis (5, 6, 36, 37), and is observed in renal cell carcinoma (38), colorectal carcinoma (39), small cell lung carcinoma (40), and melanoma (41). Thus, investigation of the molecular regulators responsible for APM component defects is clinically important in HNC and the information derived from these studies may be generally applicable to a variety of other tumor types for which immunotherapy is currently being evaluated. As mechanisms of immune escape used by tumor cells are complex and not mutually exclusive, we recognize that other suppressive effects on CTL, such as by Treg, may also cooperate to reduce elimination of tumor cells. The finding that SHP2 depletion enhances some chemottracting T111 type chemokines provides support for this approach to reverse the immunosuppressive phenotype in the microenvironment.

Previously, we showed that IFN-γ treatment could restore CTL recognition and lysis of HNC cells (4), indicating that a regulatory, as opposed to a genetic mechanism was responsible for this escape phenotype. Furthermore, HNC cells were found to express abundant levels of total STAT1, but lack phosphorylated STAT1 (9). These finding suggested that a negative regulator of STAT1 phosphorylation might be responsible for the low pSTAT1 phenotype observed. Others have shown that protein tyrosine phosphatases can dephosphorylate and inactivate STAT1 (42); therefore we investigated whether protein tyrosine phosphatases might be responsible for low basal STAT1 phosphorylation in HNC cells. Indeed, treatment of a panel of HNC cells with a broad phosphatase inhibitor, SOV, induced STAT1 phosphorylation to levels comparable or greater than those induced by IFN-γ treatment (data not shown). These data suggested that a phosphatase could contribute to the lack of pSTAT1 expression in HNC cells, maintaining a basal defect in the proapoptotic IFN-γ signal transduction pathway, and promoting immune escape. Further studies will analyze whether SHP2 overexpressed by HNC cells also contains activating mutations (30) or can be regulated by immunosuppressive cytokine(s), as suggested by others (30, 43).

The unexpected observation that SHP2 depletion not only reversed APM component downregulation and...
restored tumor antigen-specific CTL recognition of HNC cells (Figs. 3 and 5), but also induced the secretion of RANTES and IP-10 by the tumor cells (Fig. 6) has potential implications for T-cell–based immunotherapy. RANTES strongly chemoattracts several immune cells, including eosinophils, basophils, mast cells, monocytes, natural killer (NK) cells, CTLs, naïve CD4+ T cells, and memory T cells (44). RANTES also induces intratumoral infiltration of dendritic cells, CD4+ T cells, CTLs, and NK cells (45) resulting in tumor growth inhibition in vivo (46). IP-10 has also been found to have antitumor activity by attracting CD4+ T cells, CTLs, and NK cells to the tumor microenvironment (47). Indeed, successful T-cell–based immunotherapy has been linked to CXCR3 expression as a biomarker for active, tumor homing Th1 antitumor lymphocytes (35, 48).

Interestingly, MIG, another CXCR3 ligand, and MIP1-α (data not shown) and MIP1-β, CCR5 ligands, were not upregulated after SHP2 siRNA transfection, showing specificity in chemokine secretion by the tumor cells after SHP2 depletion. Blockade of several STAT1 signaling receptors, such as IFN-γR, IFN-αR, and IL-10R, did not inhibit SHP2 siRNA-mediated STAT1 phosphorylation in HNC cells (data not shown). Further work is ongoing to elucidate the STAT1 agonist(s) secreted by HNC cells following SHP2 knockdown that are responsible for STAT1 phosphorylation and induction of these chemokines, as well as their cognate receptors.

In summary, SHP2 was investigated as a negative regulator of STAT1 phosphorylation and APM components in HNC cells. These novel data strongly indicate that SHP2 overexpression in HNC tumors in vivo may contribute to APM component downregulation and CTL evasion by HNC cells. As SHP2 depletion increases the immunogenicity of HNC tumor cells, and may also induce recruitment of tumor antigen-specific immune effector cells to the tumor microenvironment. Future studies will investigate the effect of SHP2 inhibition on tumor cell growth in vivo using newly developed small-molecule targeted agents as adjuvant efforts to enhance T-cell–based immunotherapeutic approaches.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: M.S. Leibowitz, P.A.A. Filho, R.R. Seethela, S. Ferrone, R.L. Ferris
Development of methodology: M.S. Leibowitz, R.L. Ferris
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): R.M. Srivastava, P.A.A. Filho, A.M. Egloff, R.R. Seethela, R.L. Ferris
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): M.S. Leibowitz, R.M. Srivastava, A.M. Egloff, L. Wang, R.R. Seethela, S. Ferrone, R.L. Ferris
Writing, review, and/or revision of the manuscript: M.S. Leibowitz, R.M. Srivastava, S. Ferrone, R.L. Ferris
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): M.S. Leibowitz, R.L. Ferris
Study supervision: R.L. Ferris

Acknowledgments
The authors thank Drs. Amy K. Wesa (Celsense, Inc) and Yvonne K. Mburu (University of Pittsburgh) for critically reviewing the manuscript.

Grant Support
This study was supported by research funding from the NIH, grants DE019727, CA110243, CA097190, and facilities and cores of the UPCI P30 CA047904.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received May 13, 2012; revised November 13, 2012; accepted December 2, 2012; published OnlineFirst January 30, 2013.

References
SHP2 Causes pSTAT1-Dependent Immune Escape


SHP2 Is Overexpressed and Inhibits pSTAT1-Mediated APM Component Expression, T-cell Attracting Chemokine Secretion, and CTL Recognition in Head and Neck Cancer Cells

Michael S. Leibowitz, Raghvendra M. Srivastava, Pedro A. Andrade Filho, et al.

Clin Cancer Res  Published OnlineFirst January 30, 2013.

Updated version  Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-12-1517

Supplementary Material  Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2012/12/31/1078-0432.CCR-12-1517.DC1

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.